Development of oral pharmaceutical formulation of standardized crude ethanolic extract of Atractylodes lancea (Thunb) DC.

doi:10.5246/jcps.2020.04.027

Abstract

Abstract:

Cholangiocarcinoma (CCA), the adenocarcinoma of the biliary duct, is commonly reported in Asia with the highest incidence in northeastern Thailand. Chemotherapy of this type of cancer is limited due to the lack of effective chemotherapeutic drugs. A series of previous studies support further research and development of Atractylodes lancea (Thunb) DC. (AL) as a potential candidate for the treatment of CCA as a crude ethanolic extract. In the present study, we aimed to develop an oral pharmaceutical formulation (capsule) of the standardized AL crude ethanolic extract for further clinical development in patients with CCA. Major steps included macroscopic and microscopic authentication of the AL rhizomes, preparation of standardized AL extract, preparation of oral pharmaceutical formulation (capsule) of the standardized AL extract, quantitative and qualitative analysis of the marker compound (atractylodin) in the formulated AL extract, evaluation of contaminations of heavy metals, pesticides residues, and microorganisms in the ground AL rhizomes and the formulated (capsule) powder of AL, physicochemical and pharmaceutical properties of the formulatedAL extract/capsule, and cytotoxicity evaluation of the formulated AL extract. Results of all evaluations confirmed satisfactory pharmaceutical properties of oral (capsule) formulation of the standardized AL extract.

Key words: Atractylodes lancea (Thunb) DC., Capsule formulation, Atractylodin, β-Eudesmol, Cholangiocarcinoma

CLC Number:

R943

Supporting:

Thananchanoke Rattanathada, Tullayakorn Plengsuriyakarn, Rathapon Asasujarit, Anurak Cheoymang, Juntra Karbwang, Kesara Na-Bangchang. Development of oral pharmaceutical formulation of standardized crude ethanolic extract of Atractylodes lancea (Thunb) DC.[J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(4): 280-293.

References

[1] Rerknimitr, R.; Angsuwatcharakon, P.; Ratanachuek, T.; Khor, C.J.; Ponnudurai, R.; Moon, J.H.; Seo, D.W.; Pantongrag-Brown, L.; Sangchan, A.; Pisespongsa, P.; Akaraviputh, T.; Reddy, N.D.; Maydeo, A.; Itoi, T.; Pausawasdi, N.; Punamiya, S.; Attasaranya, S.; Devereaux, B.; Ramchandani, M.; Goh, K.L. Asia-Pacific consensus recommendations for endoscopic and interventional management of hilar cholangiocarcinoma. J. Gastroenterol. Hepatol. 2013, 28, 593-607.

[2] Sripa, B.; Kaewkes, S.; Sithithaworn, P.; Mairiang, E.; Laha, T.; Smout, M.; Pairojkul, C.; Bhudhisawasdi, V.; Tesana, S.; Thinkamrop, B.; Bethony, J.M.; Loukas, A.; Brindley, P.J. Liver fluke induces cholangiocarcinoma. PLoS Med. 2007, 4, e201.

[3] Ganeshan, D.; Moron, F.E.; Szklaruk, J. Extrahepatic biliary cancer: New staging classification. World J. Radiol. 2012, 4, 345-352.

[4] Na-Bangchang, K.; Plengsuriyakarn, T.; Karbwang, J. Research and development of Atractylodes lancea (thunb) DC. as a promising candidate for cholangiocarcinoma chemotherapeutics. Evid. Based Complement. Alternat. Med. 2017, 2017, 5929234.

[5] Na-Bangchang, K.; Karbwang, J. Traditional herbal medicine for the control of tropical diseases. Trop. Med. Health. 2014, 42, 3-13.

[6] Mahavorasirikul, W.; Viyanant, V.; Chaijaroenkul, W.; Itharat, A.; Na-Bangchang K. Cytotoxic activity of Thai medicinal plants against human cholangiocarcinoma, laryngeal and hepatocarcinoma cells in vitro. BMC Complement. Altern. Med. 2010, 10, 55.

[7] Patel, T. Cholangiocarcinoma: controversies and challenges. Nat. Rev. Gastroenterol. Hepatol. 2011, 8, 189-200.

[8] Thongprasert, S.; Napapan, S.; Charoentum, C.; Moonprakan, S. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann. Oncol. 2005, 16, 279-281.

[9] Ramírez-Merino, N.; Aix, S.P.; Cortés-Funes, H. Chemotherapy for cholangiocarcinoma: an update. World J. Gastrointest. Oncol. 2013, 5, 171-176.

[10] Ustundag, Y.; Bayraktar, Y. Cholangiocarcinoma: a compact review of the literature. World J. Gastroenterol. 2008, 14, 6458-6466.

[11] Wattanawongdon, W.; Hahnvajanawong, C.; Namwat, N.; Kanchanawat, S.; Boonmars, T.; Jearanaikoon, P.; Leelayuwat, C.; Techasen, A.; Seubwai, W. Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness. Int. J. Oncol. 2015, 47, 398-410.

[12] Watanabe-Galloway, S.; Flom, N.; Xu, L.Y.; Duran, T.; Frerichs, L.; Kennedy, F.; Smith, C.B.; Jaiyeola, A.O. Cancer-related disparities and opportunities for intervention in Northern Plains American Indian communities. Public Health Rep. 2011, 126, 318-329.

[13] Choudhary, N.; Sekhon, B.S. An overview of advances in the standardization of herbal drug. J. Pharm. Educ. Res. 2011, 2, 55-70.

[14] Yousef, F.; Salame, R.; Hammad, T. Formulation and evaluation of herbal tablets and hard capsules containing Urtica dioica soft extract. Int. J. Pharm. Sci. Rev. Res. 2015, 32, 98-102.

[15] Monton, C.; Saingam, W.; Suksaeree, J.; Sakunpak, A. Formulation development and physical properties study of Thai traditional herbal tablets: Jit-Tra-Rom Recipie. Int. J. Pharm. Pharm. Sci. 2014, 6, 12-21.

[16] Singh, A.; Waldia, A. Formulation and evaluation of polyherbal capsules for antidiabetic activity. WJPPS. 2015, 4, 1796-1801.

[17] Plengsuriyakarn, T.; Thitapakorn, V.; Na-Bangchang, K.; Karbwang, J. Thai medicinal plants: Potential sources of anticholangiocarcinoma drugs. Int. J. Pharm. Pharmacol. 2013, 2, 68-82.

[18] Xiao, P.G. Modern Chinese Materia Medica. Beijing: Science Press. 2002.

[19] Koonrungsesomboon, N.; Na-Bangchang, K.; Karbwang, J. Therapeutic potential and pharmacological activities of Atractylodes lancea (Thunb.) DC. Asian Pac. J. Trop. Med. 2014, 7, 421-428.

[20] Chinese Pharmacopoeia CHN, the Pharmacopoeia of the People’s Republic of China 2015, http://wp.chp.org.cn/front/chpint/en/(accessed Dec. 1, 2015).

[21] Kitajima, J.; Kamoshita, A.; Ishikawa, T.; Takano, A.; Fukuda, T.; Isoda, S.; Ida, Y. Glycosides of Atractylodes lancea. Chem. Pharm. Bull. 2003, 51, 673-678.

[22] Takeda, O.; Miki, E.; Terabayashi, S.; Okada, M.; Lu, Y.; He, H.S.; He, S.A. A comparative study on essential oil components of wild and cultivated Atractylodes lancea and A. Chinensis. Planta Med. 1996, 62, 444-449.

[23] Kohjyouma, M.; Nakajima, S.; Namera, A.; Shimizu, R.; Mizukami, H.; Kohda, H. Random amplified polymorphic DNA analysis and variation of essential oil components of Atractylodes plants. Biol. Pharm. Bull. 1997, 20, 502-506.

[24] Li, N.; Deng, C.H.; Li, Y.; Ye, H.; Zhang, X.M. Gas chromatography-mass spectrometry following microwave distillation and headspace solid-phase microextraction for fast analysis of essential oil in dry traditional Chinese medicine. J. Chromatogr. A. 2006, 1133, 29-34.

[25] Chen, Y.M.; Chou, G.X.; Wang, Z.T. Determination of beta-eudesmol in rhizome of Atractylodes lancea by RP-HPLC. China J. Chin. Mater. Med. 2007, 32, 2265-2267.

[26] Ouyang, Z.; Yang, L.; Su, S.L.; Feng, X.; Wang, M. Fingerprint of volatile oil of Atractylodes lancea by GC-MS. Acta Pharm. Sin. 2007, 42, 968-972.

[27] Plengsuriyakarn, T.; Viyanant, V.; Eursitthichai, V.; Picha, P.; Kupradinun, P.; Itharat, A.; Na-Bangchang, K. Anticancer activities against cholangiocarcinoma, toxicity and pharmacological activities of Thai medicinal plants in animal models. BMC Complement. Altern. Med. 2012, 12, 23.

[28] Plengsuriyakarn, T.; Matsuda, N.; Karbwang, J.; Viyanant, V.; Hirayama, K.; Na-Bangchang, K. Anticancer activity of Atractylodes lancea (thunb.) DC in a hamster model and application of PET-CT for early detection and monitoring progression of cholangiocarcinoma. Asian Pac. J. Cancer Prev. 2015, 16, 6279-6284.

[29] Martviset, P.; Chaijaroenkul, W.; Muhamad, P.; Na-Bangchang, K. Bioactive constituents isolated from Atractylodes lancea (Thunb.) DC. rhizome exhibit synergistic effect against cholangiocarcinoma cell. J. Exp. Pharmacol. 2018, 10, 59-64.

[30] Tunsirikongkon, A.; Kraisit, P.; Seubsasana, S.; Itharat, A.; Sarisuta, N. Formulation Development of Herbal Capsule containing Oleoresin of Zingiber officinale Extract. Int. J. Pharm. Pharm. Sci. 2013, 5, 439-445.

[31] Jhade, D.; Ahirwar, D.; Jain, R.; Sharma, N.; Gupta, S. Pharmacognostic standardization, physico- and phyto-chemical evaluation of Amaranthus spinosus linn. Root. J. Young Pharm. 2011, 3, 221-225.

[32] Borhade, P.S.; Deshmukh, T.A.; Patil, V.R.; Khandelwal, K.R. Pharmacognostic and Phytochemical Investigations of Plumbago zeylanica Linn. root. J. Pharmacogn. Phytochem. 2014, 2, 83-88.

[33] U.S. Department of Health and Human Services F, and Drug Administration aCfDEa, (CDER) R, Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteer, Guidance for Industry 2005.

[34] Verma, S.C.; Jain, C.L.; Rani, R.; Pant, P.; Singh, R.; Padhi, M.M.; Devalla, R.B. Simple and rapid method for identification of Curcuma longa rhizomes by physicochemical and HPTLC fingerprint analysis. Chem. Sci. Trans. 2012, 1, 709-715.

[35] Atractylodis Rhizoma HK, Hong Kong Chinese Materia Medica Standards 2012.

[36] Thai Herbal Pharmacopoeia THA, Department of Medical Science, Ministry of Public Health 2017.

[37] British Pharmacopoeia UK, British Pharmacopoeia 2018.

[38] Convention TUSP, U.S. Pharmacopeia 41, National Formulary 362018.

[39] Rane Rajashree, G.D.; Sushma, P.; Kanchan, I. Formulations as Herbal Medicines and Nutraceuticals. Res. J. Pharmaceutical. Sci. 2012, 1, 10-15.

[40] USP Controlled Room Temperature Range Expansion 2014.

[41] Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 1983, 65, 55-63.

[42] Bhatt, D.; Jethva, K.; Patel, S.; Zaveri, M. Development and standardization of Polyherbal formulation for the management of breast cancer. Int. J. Pharm. Sci. Res. 2017, 2. 24-28.

[43] Hunt, D.G.; Chandler, C.; Ulrich, D.A.; Poska, R.; Montero, A. USP Controlled Room Temperature Range Expansion. Pharmacopeial. Forum. 2013, 39, 1-5.

[44] Zhu, S.D.; Peng, H.S.; Guo, L.P.; Xu, T.R.; Zhang, Y.; Chen, M.L.; Hao, Q.X.; Kang, L.P.; Huang, L.Q. Regionalization of Chinese Material Medical Quality Based on Maximum Entropy Model: A case study of Atractylodes lancea. Sci. Rep. 2017, 7, 42417.